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Objectives: The current study examined the trends in the incidence and prevalence 
of type 2 diabetes mellitus (T2DM) in the Medicare population. MethOds: A prospec-
tive population-based study was performed from January 1, 2008 through December 
31, 2013, to determine the prevalence and incidence of patients diagnosed with T2DM 
(International Classification of Disease, 9thRevision, Clinical Modification diagnosis 
codes 250.x0 and 250.x2) from the Medicare population. Patients with continuous 
enrollment in fee-for-service Medicare throughout the calendar year and at least 2 
years prior, were included for study. The age- and gender-adjusted prevalence and 
incidence (overall and specified by age group and gender) of T2DM were calculated 
using direct standardization to the U.S. population aged 65 years or older in 2010, 
using gender-specific age groups. Results: The annual adjusted overall prevalence 
of T2DM increased from 27.92% in 2008 to 32.00% in 2013, whereas the annual overall 
incidence rate decreased from 4.60% in 2008, to 2.79% in 2013. T2DM prevalence and 
incidence rates were higher among men compared to women, every year. Patients 
aged 80-84 had the highest prevalence rate in 2008 (30.40%) and 2011 (36.16%), whereas 
in 2012 (37.46%) and 2013 (38.57%), patients aged 85-89 had the highest prevalence 
rates. From 2008 to 2013, there was a steady growth in the prevalence rates among 
patients older than 75. In 2008, the highest T2DM incidence was observed in the Virgin 
Islands (9,885 per 100,000 person-years). In 2013, the highest incidence of T2DM was 
in New Jersey (6,143 per 100,000 person-years). cOnclusiOns: From 2008 to 2013, 
T2DM prevalence increased and incidence decreased. Men were more likely to be 
diagnosed with T2DM compared to women.
PDB19
ImPact of SocIoeconomIc StatuS on the Prevalence of 
comPlIcatIonS In tyPe 2 DIaBeteS In InDIan PoPulatIon: a SyStematIc 
revIew
Esam H, Mothe RK, Vsn M, Likhar N, Dang A
MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India
Objectives: India as said to be the diabetic capital of the world. This systematic 
review aims to determine the association between socioeconomic status (SES) and 
complications associated with Type 2 Diabetes Mellitus. MethOds: Literature 
search was conducted in databases such as PubMed, EMBASE and the Cochrane 
library without any restrictions. References of the included studies were screened 
for additional studies. We included observational studies focussing on association 
between SES and T2DM patients. The quality of the studies was assessed using the 
Newcastle-Ottawa scale. Two authors independently performed the study selection, 
data extraction and the quality assessment process. A third author reviewed the 
output and adjudicated discussions in case of disagreement. Results: A total of 
440 studies were retrieved by the databases search, of which only 4 studies were 
included in the final review. One study reported that T2DM population with SES 
groups were at high risk for developing visual impairment (odds ratio [OR] 2.91; 95% 
confidence interval [CI] 1.24-6.85). Similarly, another study showed high prevalence 
of diabetes peripheral neuropathy in lower SES (48.4%) group compared to upper 
SES group (10.2%). A positive association of cataract was observed in low SES group 
compared to higher SES group (OR 1.67; 95% CI 1.10-2.54; one study). In contrast to 
these findings, one study reported no significant differences between SES groups 
in the occurrence of any form of micro-vascular complications. cOnclusiOns: 
The present review found very limited evidence regarding the association between 
socioeconomic status and diabetes complications. The available evidence suggest 
that diabetic peripheral neuropathy and eye related complications are high in low 
SES population, suggesting the need for educating patients with low SES to prevent 
long term complications in Indian T2DM patients. More observational studies are 
required to be conducted in the future in this context.
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Objectives: The aim of the study was to explore the association of waist circumfer-
ence with glycaemic control in Malaysian patients with type 2 diabetes. MethOds: 
We utilised data of type 2 diabetes patients followed up in Malaysian public sec-
tor primary care clinics contained in the National Diabetes Registry in the year 
2012. The variable of interest was poor glycaemic control, defined as HbA1c≥ 6.5%. 
Multiple logistic regression was used to explore the association between glycae-
mic control and waist circumference, which was adjusted for age, sex, duration of 
diabetes, systolic blood pressure, total cholesterol, use of insulin and other medica-
tions. Results: A total of 98,825 patients with type 2 diabetes were included in the 
study. The mean age of patients was 59.9 years (SD: 10.9) and 38.9% were males. The 
mean duration of diabetes was 6.8 years (SD: 5.0) and 76.2% of patients had HbA1c 
≥ 6.5%. The mean waist circumference was 94.0 cm (SD: 11.8) for male and 90.7 cm 
(SD: 11.8) for female; while 78.3% of the patients had waist circumference above the 
cut-off (≥ 90 cm for men and ≥ 80 cm for women). Larger waist circumference was 
found to be significantly associated with HbA1c≥ 6.5% (adj. OR 1.009; p< 0.001; 95% 
CI: 1.007–1.011) after adjusting for confounding factors. cOnclusiOns: Analysis 
showed that glycaemic control was poorer in patients with higher waist circumfer-
ence than in patients with lower waist circumference.
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Prevalence and incidence rates of AD use were calculated for each calendar year and 
stratified by class therapy and age group. Sub-analyses by cardiovascular co-medi-
cation therapy and pharmaceutical cost analysis were performed. Results: Overall, 
the prevalence rate decreases from 22.0%-17.5% 2010-2014 (p< 0.001). Proportion of 
subjects treated with monotherapy increases over the study period (33,9%-38,6% 2010-
2014; p< 0.001). In particular, increases the proportion of users of metformin (18,2%-
23,7% 2010-2014; p< 0.001), while the proportion of users of sulfonylureas dropped 
(11,0%-7,2% 2010-2014; p< 0.001). Overall about 90% of elderly diabetic patients are 
treated with drugs for cardiovascular prevention. The largest increase during the study 
period occurred in subjects aged 65-74 years (54.8%-62.1% 2010-2014; p< 0.001). On the 
other hand the trend was downward both in the 75-84 and in ≥ 85 age groups (37.3%-
32.9% 2010-2014; 7.8%-5.0% 2010-2014 respectively). The per/patient/yearly drug costs 
was 2,349€ : 28.5% for AD therapy and 71.5% for other treatments. cOnclusiOns: 
The results confirm the negative trends observed in other population in the use of 
AD drugs among elderly diabetic patients. Specific trend in drug utilization patterns 
showed an increased attention towards treatment recommendations in older adults. 
Safety concerns in the elderly regarding polypharmacy such as presence of multi-
morbidity and hypoglycemic episodes could also have contributed to such a trend.
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Objectives: Diabetes mellitus type 2 (T2DM) is associated with an elevated risk of 
microvascular and macrovascular complications that are the leading cause of morbid-
ity and mortality in this patient population. In 2008, the Food and Drug Administration 
(FDA) has provided guidance for industry on how to demonstrate that new antidia-
betic drugs for T2DM are not associated with an unacceptable increase in cardiovas-
cular risk. Since introduction of the AMNOG in Germany in the year 2011, the Federal 
Joint Committee has consistently demanded the analysis of cardiovascular outcomes 
for new antidiabetics. The objective of this study is to analyze the cardiovascular risk 
associated with antidiabetics by a literature search. MethOds: To identify long-term 
outcomes studies, a targeted literature research was conducted in PubMed in 2015, 
using the search terms Diabetes Mellitus, Type 2/ drug therapy/ epidemiology/ cardio-
vascular. Included studies were categorized regarding study design, patient-inclusion 
criteria, pre-existing illness, treatment duration, treatment modus and cardiovascular 
outcomes. PubMed research was supplemented by additional searches in guidelines 
in German/English language. Results: 15 outcome studies were identified in T2DM: 
UKPDS, PROactive, STOP/NIDDM, ACCORD, ADVANCE, VADT, SAVOR-TIMI, EXAMINE, 
NAVIGATOR, RECORD, Look AHEAD, ORIGIN. Studies TECOS (sitagliptin) and ELIXA 
(lixisenatide) have reported results until mid of 2015 while data from EMPA-REG 
OUTCOMETM(empagliflozin) are expected in the second half of 2015. Combined or 
single cardiovascular outcomes were used as primary endpoints by 12 studies. None 
of the outcome studies in T2DM with cardiovascular condition that have reported 
results so far could demonstrate a significant risk reduction for macrovascular events 
in the primary endpoint. cOnclusiOns: Cardiovascular outcome studies of new 
antidiabetics are important to analyse safety of therapies as well as long-term condi-
tions and unmet need in T2DM. Especially the results of the ongoing studies are bound 
to fill the gap stressed by marketing-authorization and reimbursement agencies.
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Objectives: To explore demographic and clinical factors associated with choice 
of type 2 diabetes mellitus (T2DM) treatment at time of treatment intensifica-
tions. MethOds: For T2DM patients from the Netherlands (NL), Italy (IT), Spain 
(ES) (2007-2011) and United Kingdom (UK) (2008-2012) antidiabetic drug prescription 
records were obtained from electronic health-care record databases. Oral mono-
therapy was defined as first-line, oral dual therapy as second-line, > 2 oral treat-
ments or oral combined with an injectable as third-line and injectables only as 
fourth-line treatment. Treatment intensification was defined as starting a higher 
line of treatment. General characteristics, comedication, comorbidities and clinical 
parameters associated with choice of treatment were identified using multivariate 
logistic regression. Results: From NL, IT, ES and UK 48,479, 67,751, 348,572 and 
152,544 T2DM patients were included, respectively. For first-line treatment advanced 
age and renal comorbidity were associated with SU (all countries), whereas high 
BMI was inversely associated in UK and ES. For second-line treatment advanced age 
was associated with biguanide + SU (all countries) and renal comorbidity with SU + 
dipeptidyl peptidase-4 inhibitors (DPP4) in UK and NL. High BMI was associated with 
biguanide + thiazolidinedione (TZD) in UK and ES, and with biguanide + DPP4 (UK 
only). For third-line treatment advanced age and renal comorbidity were associated 
with SU + insulin in ES and UK, but high BMI was inversely associated with any 
third-line treatment containing insulin. For fourth-line treatment women were more 
likely to receive glucagon-like peptide-1 analogs than men in UK and ES. Calendar 
year and prior treatment played differing roles in treatment choices in different 
countries. cOnclusiOns: Age, BMI and renal comorbidity were the predominant 
factors associated with T2DM treatment choice across treatment intensifications 
in four EU countries. Associations identified in this explorative study are intended 
to identify questions for further research.
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inclusion of the symptoms. The heterogeneity in defining hypoglycaemia makes 
it difficult to compare the safety of interventions for their drug-induced hypogly-
caemia.
DIaBeteS/enDocrIne DISorDerS – cost Studies
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Objectives: To estimate the incremental budget impact of the reimbursement 
of long-acting insulin analogues (LAIA) for type 1 diabetes patients (T1DM) in 
Brazil. MethOds: A budget impact analysis (BIA) of LAIA in the Brazilian 
public health system compared to NPH human insulin was performed. The 
analysis’ time horizon was 5 years. The target population used the methodology 
of epidemiological demand, considering estimates of the International Diabetes 
Federation: 11.6 million diabetics of 20-79 years old x 5% T1DM plus 31100 chil-
dren and 10845 adolescents. It considered the incidence of 10.4/100,000 persons 
per year and mortality 23.15/1000 adults per year. The overall mean insulin dose 
was obtained from trials. For the human insulin, we considered the values of last 
purchase of the Ministry of Health. For both insulins, we got the average maxi-
mum sale price for government from CMED list. Then the bargaining power was 
calculated dividing the NPH’s maximum sale price by the Ministry’s purchase 
price, and we applied 50% of the bargaining power to the LAIA’s price. Market 
share was 50%, 60%, 70%, 80% and 80%. Results: The incremental budget 
impact of LAIA would be $93 million in the 1st year, considering 50% of target 
population, and reaching approximately $432 million for 80% of patients. In 5 
years, the calculated budget impact was $617 million. The sensitivity analysis 
indicates the prevalence and analogues prices as villains. cOnclusiOns: LAIA 
are available in Brazil since 2002, although to this day the public health system 
does not make it available to citizens. We can suggest that the reason for non-
coverage is the considerable budget impact, nevertheless our analysis, more com-
plex and with rational methodology, have shown less impact than the analysis 
used in the Ministry’s decision, which BIA was U$ 816 million for the coverage 
of LAIA.
PDB25
the nhS exPenDIture manaGInG Severe hyPoGlycemIa ePISoDeS In tyPe 
2 DIaBetIc PatIentS In PortuGal
Laires PA1, Conceição J1, Araújo F2, Dores J3, Silva C4, Radican L5, Nogueira AM1
1Merck Sharp & Dohme, Oeiras, Portugal, 2Hospital Beatriz Angelo, Loures, Portugal, 3Hospital 
Santo António, Porto, Portugal, 4Eurotrials, Scientific Consultants, Lisbon, Portugal, 5Merck Sharp 
& Dohme Corp., Rahway, NJ, USA
Objectives: Hypoglycemia is an acute complication of diabetes that increases 
the morbidity, mortality and disease costs. We aimed to estimate the annual NHS 
expenditure managing severe hypoglycemia episodes in type 2 diabetic patients 
in Portugal. MethOds: HIPOS-ER (Hypoglycemia in Portugal Observational Study 
– Emergency Room) study was an observational, cross-sectional, multicenter, 
hospital-based study conducted in seven centers of Portugal mainland within a 
period of 12 months (January 2013 - January 2014). Patient level data were used 
to quantify healthcare resource consumption related to emergency transporta-
tion, emergency department care and hospitalization. Unit costs for 2014 were 
extracted from official sources and reported in euros. Results: A total of 425,706 
admissions at the emergency room were registered in the participating hospitals 
within the shifts covered by HIPOS-ER study. Of these, 0.074% had diabetes type 2 
and were admitted due to an episode of hypoglycemia meaning that theoretically 
2.317 emergencies occur yearly in Portugal due to severe hypoglycemia in Type 
2 diabetic patients (out of an universe of 3.131.126 annual general emergencies 
in Portugal). Considering the HIPOS-ER estimated mean cost for managing this 
type of hypoglycemia (i.e. € 1,479), we expect that around 3.4 millions of euros 
per year are spent in treating this diabetes related complication at emergency 
rooms of NHS Portuguese hospitals. cOnclusiOns: Our estimation highlights 
the potential overall economic burden of severe hypoglycemias in Portugal, mean-
ing that this diabetes-related event must be taken in consideration by different 
healthcare stakeholders not only from strict clinical point of view, but also from 
and economic one. We conclude that severe hypoglycemic events represent a sub-
stantial cost for society and in particular for the hospitals of the National Health 
Service.
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Objectives: Background: The DPP4 inhibitors are among the newer, yet more estab-
lished, classes of diabetes medications. In the US these include: sitagliptin, saxa-
gliptin, linagliptin, and alogliptin. OBJECTIVE: The objective was to compare direct 
medical costs for patients taking DPP4-inhibitors. MethOds: Claims were extracted 
for Humana Medicare or Commercial plan members with > = 1 prescription filled 
for a DPP4-inhibitor between July 1, 2011 and March 31, 2013. The first prescription 
claim for a DPP4 established the index date and index medication, and 12-month 
pre- and post-index data were analyzed. The Diabetes Complications Severity Index 
(DCSI) assessed diabetes-related co-morbidities. Post-index costs (in 2013 US dol-
lars) were compared adjusting for pre-index costs, DCSI, pre-index insulin, age and 
gender using GLMs and p < 0.05. Results: Few patients were prescribed alogliptin. 
The final samples included 22,860 patients with Medicare coverage (17,292 sitagliptin; 
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Objectives: The aim of this study was to analyse which factors predict the real-
world macro-/microvascular event, hospitalisation and death risk in patients with 
type 2 diabetes mellitus (T2DM). MethOds: We used a German claims/clinical data 
set (AOK Plus) covering the years 2010-12. Factors associated with event risk were 
analysed by a Kaplan-Meier curve analysis and by multivariable Cox regression mod-
els. Results: 229,042 T2DM patients (mean age 70.2 years; mean CCI 6.03). A total 
of 66.3% of the sample had a mean systolic blood pressure of > 130mmHg (mean: 
135.56mmHg), 48.0% could be considered as obese (BMI> 30). The mean HbA1C in 
the sample was 7.00%; 11.1% of observed patients had a mean HbA1C< 6.0%, 75.3% 
< 7.5%, and 4.5% ≥ 9.0%. The mean observational period per patient from 01/04/2011 
until 31/12/2012 or until first observed all-cause event was 581.9 days (SD: 148.4). 
39,589 patients of the study sample (17.3%) were affected by at least one T2DM-
related event in this period (event frequency per 1,000 patient years: 82.7 macrovas-
cular events; 10.8 microvascular events; 28.4 hospitalisations with T2DM as main 
diagnosis; 40.7 deaths). Among factors that increased the composite event risk were 
patients’ age, male gender, the adapted Charlson-Comorbidity-Index, the adapted 
Diabetes-Complication-Severity Index, previous events, and number of prescribed 
chronic medications. For systolic blood pressure/HbA1C, a double-J/U-curve pattern 
was detected: HbA1C of 6-6.5% and systolic blood pressure of 130-140mmHg were 
associated with the lowest event risk, values below/above that range were associ-
ated with higher risk. However, this pattern was mainly driven by the death risk 
and was much less clearly observed for the macrovascular/microvascular/hospi-
talization risk and for young/less comorbid patients. cOnclusiOns: Both blood 
pressure and HbA1C seem to be very important treatment targets, especially in 
comorbid old patients. Both over- and under-treatment pose a threat to patients 
with type 2 diabetes mellitus.
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Objectives: Patients with type 2 diabetes mellitus (T2DM) display a unique skel-
etal phenotype with either normal or more frequently increased, bone mineral 
density and impaired structural and geometric properties. Alterations in bone 
material properties seem to be the predominant defect leading to increased bone 
fragility. A systematic review and meta-analysis of observational studies is con-
ducted to assess the association between T2DM and fracture risk. MethOds: A 
systematic literature search was performed in Medline and EMBASE databases. 
“Abstracts” from annual scientific meeting of various diabetes and bone and min-
eral societies were also searched to identify relevant studies. Studies reporting 
fracture risk in subjects with T2DM in comparison with subjects without diabetes 
were included. Heterogeneity was calculated by performing I2 statistics. Summary 
relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated 
using random-effects model. Results: Twelve studies met the inclusion criteria 
reporting 25,848 fracture events among 6,12,748 subjects without diabetes (4.2 %) 
and 8570 fracture events among 2,12,011 subjects with T2DM (4.0 %). The pooled 
relative risk (RR) of any fracture in subjects with T2DM was 0.91 (95% CI 0.75 – 1.11, 
p= 0.375). The pooled RR for any fractures in women with T2DM was 0.907 (95% 
CI 0.735- 1.118, 10 studies) compared to subjects without diabetes. The pooled RR 
for any fractures in men with T2DM was 0.868 (95% CI 0.738 to 1.022) compared 
to subjects without diabetes. Sensitivity analysis demonstrated stability of result 
after removing outliers. No publication bias was observed on visual analysis of 
funnel plot. cOnclusiOns: Our meta-analysis suggests that patients of T2DM 
are not at increased risk of incidence of fractures as compared to non diabetic 
subjects.
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Objectives: To examine the heterogeneity in the definitions of hypoglycaemia 
across Randomized Clinical Trials (RCTs) conducted with oral antidiabetic agents 
or insulin. MethOds: RCTs included in the Canadian Agency for Drugs and 
Technologies in Health (CADTH) reports for the second-line and third-line therapy 
for the patients with Type 2 Diabetes were examined. Definitions for overall, major, 
minor, severe, and nocturnal hypoglycaemia were extracted from 76 RCTs. The 
extracted definitions were compared to the definitions of the American Diabetes 
Association (ADA) and European Medicines Agency (EMA). Results: According to 
the ADA and the EMA, hypoglycaemia is defined as an event with a blood glucose 
(BG) ≤ 3.9mmol/L. Only 4 out of 76 studies adhered to the ADA/EMDA definition of 
hypoglycaemia. Generally, hypoglycaemia was defined as a status with BG rang-
ing from < 4 mmol/L to ≤ 2.8mmol/L. Only 17 out of 33 RCTs that defined severe 
hypoglycaemia adhered to the ADA/ EMDA definition. Severe hypoglycaemia was 
defined as a symptomatic condition that required the assistance of a third person 
for resuscitative actions, with or without BG values spanning from < 3.3 mmol/L to 
< 2.0 mmol/L. Major hypoglycaemia was defined as patients being unable to treat 
themselves, with or without a BG value ranging from < 3.1 mmol/L to ≤ 2.8 mmol/L. 
Nocturnal hypoglycaemia was vaguely defined when reported, as episodes occurring 
after evening injection and before breakfast, or between bedtime and morning, or 
any 6 hours or longer interval between 11pm and 8am. cOnclusiOns: Compared 
to the ADA and EMA proposed definitions of hypoglycaemia (BG≤ 3.9mmol/L), the 
studies included in our review had a substantial heterogeneity in their definitions 
of hypoglycaemia not only in terms of the BG values being used, but also with the 
